Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

Vaccitech's six products are all in early stage trials or pre-clinical testing, and are all based on the viral vector vaccine technology. The vaccines can be used as treatment or prophylaxis ...

Despite decades of efforts, tuberculosis remains a global health crisis, claiming over 1.3 million lives annually. In a ...

Strengthening U.S. Biodefense. ATLANTA, GA - March 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapi ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

That’s the view of analysts at Jefferies, who suggest it could “re-ignite concerns over the use of lentiviral vectors and the risk of secondary (vector-mediated) cancer".

The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for ...

In this case, although a vaccine made by inactivated viral surface antigen (HBsAg) was shown to be effective in the seventies, vaccine manufacture was limited since the antigen could only be ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

WHO highlights encephalitis as a public health priority, urging a national strategy to tackle the disease effectively.

Social media users were perplexed by the scene in a viral clip, with one saying "my brain flatlined for a second there." ...

LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of ...